| 发明名称 |
STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS |
| 摘要 |
The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions. |
| 申请公布号 |
US2014178357(A1) |
申请公布日期 |
2014.06.26 |
| 申请号 |
US201314088169 |
申请日期 |
2013.11.22 |
| 申请人 |
Baxter Healthcare S.A. ;Baxter International Inc. |
发明人 |
Matthiessen Peter;Turecek Peter L.;Schwarz Hans-Peter |
| 分类号 |
A61K9/19;A61K38/48 |
主分类号 |
A61K9/19 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A stabilized formulation of ADAMTS13, comprising:
(a) 0.05 mg/ml to 10.0 mg/ml ADAMTS13; (b) 0 mM to 200 mM of a pharmaceutically acceptable salt (c) 0.5 mM to 20 mM calcium; (d) a sugar and/or sugar alcohol; (e) a nonionic surfactant; and (f) a buffering agent for maintaining a pH between 6.0 and 8.0. |
| 地址 |
Glattpark (Opfikon) CH |
